Search

Your search keyword '"Mangoni, M."' showing total 525 results
Start Over Author "Mangoni, M."
525 results on '"Mangoni, M."'

3. Lipopolysaccharide-induced sepsis impairs M2R-GIRK signaling in the mouse sinoatrial node

Author

Shrestha, N, Zorn-Pauly, K, Mesirca, P, Koyani, C, Wölkart, G, Biase, V, Torre, E, Lang, P, Gorischek, A, Schreibmayer, W, Arnold, R, Maechler, H, Mayer, B, von Lewinski, D, Torrente, A, Mangoni, M, Pelzmann, B, Scheruebel, S, Shrestha N., Zorn-Pauly K., Mesirca P., Koyani C. N., Wölkart G., Biase V. D., Torre E., Lang P., Gorischek A., Schreibmayer W., Arnold R., Maechler H., Mayer B., von Lewinski D., Torrente A. G., Mangoni M. E., Pelzmann B., Scheruebel S., Shrestha, N, Zorn-Pauly, K, Mesirca, P, Koyani, C, Wölkart, G, Biase, V, Torre, E, Lang, P, Gorischek, A, Schreibmayer, W, Arnold, R, Maechler, H, Mayer, B, von Lewinski, D, Torrente, A, Mangoni, M, Pelzmann, B, Scheruebel, S, Shrestha N., Zorn-Pauly K., Mesirca P., Koyani C. N., Wölkart G., Biase V. D., Torre E., Lang P., Gorischek A., Schreibmayer W., Arnold R., Maechler H., Mayer B., von Lewinski D., Torrente A. G., Mangoni M. E., Pelzmann B., and Scheruebel S.

Abstract

Sepsis has emerged as a global health burden associated with multiple organ dysfunction and 20% mortality rate in patients. Numerous clinical studies over the past two decades have correlated the disease severity and mortality in septic patients with impaired heart rate variability (HRV), as a consequence of impaired chronotropic response of sinoatrial node (SAN) pacemaker activity to vagal/parasympathetic stimulation. However, the molecular mechanism(s) downstream to parasympathetic inputs have not been investigated yet in sepsis, particularly in the SAN. Based on electrocardiography, fluorescence Ca2+ imaging, electrophysiology, and protein assays from organ to subcellular level, we report that impaired muscarinic receptor subtype 2-G protein-activated inwardly-rectifying potassium channel (M2R-GIRK) signaling in a lipopolysaccharide-induced proxy septic mouse model plays a critical role in SAN pacemaking and HRV. The parasympathetic responses to a muscarinic agonist, namely IKACh activation in SAN cells, reduction in Ca2+ mobilization of SAN tissues, lowering of heart rate and increase in HRV, were profoundly attenuated upon lipopolysaccharide-induced sepsis. These functional alterations manifested as a direct consequence of reduced expression of key ion-channel components (GIRK1, GIRK4, and M2R) in the mouse SAN tissues and cells, which was further evident in the human right atrial appendages of septic patients and likely not mediated by the common proinflammatory cytokines elevated in sepsis.

Published
2023

4. Cardiological Safety of 5-Fraction Whole Breast Irradiation

Author

Becherini, C., primary, Livi, L., additional, Barletta, G., additional, Marrazzo, L., additional, Bellini, C., additional, Scoccimarro, E., additional, Bettazzi, B., additional, Lorenzetti, V., additional, Banini, M., additional, Salvestrini, V., additional, Visani, L., additional, Valzano, M., additional, Loi, M., additional, Francolini, G., additional, Casati, M., additional, Bene, M. R. Del, additional, Pilato, G., additional, Mangoni, M., additional, Pallotta, S., additional, and Meattini, I., additional

Published
2023
Full Text
View/download PDF

5. The Role of Stereotactic Radiotherapy in Deferring the Need for Systemic Therapies in Patients with Progressive Oligometastatic Iodine-Refractory Thyroid Cancer

Author

Simontacchi, G., primary, Sparano, C., additional, Loi, M., additional, Mangoni, M., additional, Olmetto, E., additional, Garlatti, P., additional, Scoccimarro, E., additional, Frosini, G., additional, Bertini, N., additional, Morelli, I., additional, Romei, A., additional, Orsatti, C., additional, Pallotta, S., additional, Calusi, S., additional, Cataldo, V. Di, additional, and Livi, L., additional

Published
2023
Full Text
View/download PDF

8. PD-0576 Stereotactic reirradiation for locally recurrent prostate cancer after definitive radiotherapy

Author

Francolini, G., primary, Cerbai, C., additional, Carnevale, M.G., additional, Di Cataldo, V., additional, Detti, B., additional, Loi, M., additional, Frosini, G., additional, Guerrieri, B., additional, Morelli, I., additional, Roghi, M., additional, Ganovelli, M., additional, Allegra, A., additional, Salvestrini, V., additional, Visani, L., additional, Olmetto, E., additional, Greto, D., additional, Simontacchi, G., additional, Mangoni, M., additional, Desideri, I., additional, Meattini, I., additional, and Livi, L., additional

Published
2023
Full Text
View/download PDF

9. PO-1269 Cardiological monitoring and safety of 5-fraction whole breast irradiation: SAFE-FORWARD study

Author

Becherini, C., primary, Bellini, C., additional, Barletta, G., additional, Visani, L., additional, Marrazzo, L., additional, Scoccimarro, E., additional, Cerbai, C., additional, Frosini, G., additional, Peruzzi, A., additional, Bonaparte, I., additional, Bettazzi, B., additional, Lorenzetti, V., additional, Salvestrini, V., additional, Valzano, M., additional, Mangoni, M., additional, Casati, M., additional, Pallotta, S., additional, Meattini, I., additional, and Livi, L., additional

Published
2023
Full Text
View/download PDF

11. PO-1391 Dose intensification in Locally Advanced Pancreatic Cancer using Robotic SBRT

Author

valzano, M., primary, Loi, M., additional, Bonomo, P., additional, Masi, L., additional, Doro, R., additional, Salvestrini, V., additional, Banini, M., additional, Lorenzetti, V., additional, Morelli, I., additional, Romei, A., additional, Di Cataldo, V., additional, Francolini, G., additional, Greto, D., additional, Mangoni, M., additional, Simontacchi, G., additional, and Livi, L., additional

Published
2023
Full Text
View/download PDF

12. Radiobiology of stereotactic radiotherapy

Author

Mangoni, M., Borghesi, S., Aristei, C., and Becherini, C.

Subjects
Oncology, Stereotactic radiotherapy, Radiobiology, Radiology, Nuclear Medicine and imaging, Radiosurgery
Abstract

This paper focuses on the radiobiological mechanisms underlying the effects of stereotactic radiotherapy (SRT ) which, despite SRT expansion, have not yet been fully elucidated. Some authors postulated that radiobiology principles, as applied to conventional fractionations (5R: reoxygenation, repair, repopulation, redistribution, radioresistence), suffice in themselves to account for the excellent clinical results of SRT; others argued that the role of the 5R was limited. Recent preclinical data showed that hypofractionated ablative treatments altered the microenvironment, thus determining cell death either directly or indirectly. Furthermore, dead tumor cells released quantities of antigens, which stimulated antitumor immunity, thus reducing the risk of relapse and metastasis. Better understanding of the radiobiological mechanisms underlying response to high-dose radiation treatment is essential for predicting its short- and long-term effects on the tumor and surrounding healthy tissues and, consequently, for improving its related therapeutic index.

Published
2022
Full Text
View/download PDF

13. Preoperative Radiosurgery on Early Breast Cancer Patients: Analysis of Tumor Genetic Background and Tumor Immune Microenvironment.

Author

Loi, M., Mangoni, M., Duatti, A., Caini, S., Fiorito, G., Salvatore, G., Anichini, G., Sottili, M., Visani, L., Francolini, G., Cataldo, V. Di, Becherini, C., Salvestrini, V., Bianchi, S., Stefano, G. Di, Greto, D., Simontacchi, G., Desideri, I., Meattini, I., and Livi, L.

Subjects
*EPIDERMAL growth factor receptors, *GENE expression, *TUMOR classification, *SURGICAL robots, *FALSE discovery rate
Abstract

A phase II trial was conducted to assess the feasibility, safety, and activity of a single 21 Gy preoperative robotic radiosurgery (prRS) in early breast cancer patients, 50+ years old, hormonal receptors positive/human epidermal growth factor receptor 2 negative (HR+/HER2-), sized up to 25 mm. Breast surgery was performed 2 to 4 weeks after radiosurgery. A translational study was carried out to explore the modulation of tumor-immune microenvironment before and after irradiation and the transcriptome on tumor samples before irradiation. Among the 70 patients recruited, 22 patients were successfully treated with prRS. Fresh pre-treatment tumor biopsies and fresh post-radiosurgery and post-operative tumor samples were retrieved. For immunohistochemistry analysis, pre-radiosurgery biopsies and post-operative tumors were stained with specific antibodies to evaluate the expression of different immune-related biomarkers. For the transcriptome analysis, total RNA was extracted from frozen pre-treatment samples and RNA sequencing was performed by using a total of 10 ng/uL. The statistical analyses aiming at detecting differences in gene expression according to tumor downstaging were conducted by fitting age-adjusted linear regression models, and applying the false discovery rate (FDR) method for correcting for multiple tests. As clinical output, we considered tumor downstaging according to pTNM and patients were classified as Radio-Responders (R-R = 8) and non-Radio-Responders (nR-R = 13) after prRS. IHC was performed on available 19 pairs of pre- and post-irradiation tissues for evaluation of CD68, CD163, CD4, CD8, CD56 and CD16: preliminary analysis showed a marked increase in CD68, CD163 and CD4 staining after tumor prRS. RNAseq results showed 170 differentially expressed genes between R-R and nR-R. Statistical analysis identify CCDC97 and MDIFC as genes that were significantly up- and down-regulated respectively in R-R patients. CCD97 is an orphan gene previously described as part of a nuclear interactome with functional role in DNA damage repair, while MDFIC is reported to be associated with pro- or anti-tumoral functions as chemoresistance induction or cell proliferation inhibition. The phase II trial enrolled 22 patients; this little number limits the statistical power of results obtained in the translational analysis. Based on the preliminary results, IHC analysis showed that prRS modulates the immune microenvironment composition in early breast cancer patients. Furthermore, we hypothesized that the differential expression of CCDC97 and MDFIC may play a role in prRS response. The role of orphan genes CCDC97 and MDFIC in response to radiation and to hypofractionation makes worthy further pre- and clinical investigations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. ESC working group on cardiac cellular electrophysiology position paper: Relevance, opportunities, and limitations of experimental models for cardiac electrophysiology research

Author

Odening, K, Gomez, A, Dobrev, D, Fabritz, L, Heinzel, F, Mangoni, M, Molina, C, Sacconi, L, Smith, G, Stengl, M, Thomas, D, Zaza, A, Remme, C, Heijman, J, Odening K. E., Gomez A. -M., Dobrev D., Fabritz L., Heinzel F. R., Mangoni M. E., Molina C. E., Sacconi L., Smith G., Stengl M., Thomas D., Zaza A., Remme C. A., Heijman J., Odening, K, Gomez, A, Dobrev, D, Fabritz, L, Heinzel, F, Mangoni, M, Molina, C, Sacconi, L, Smith, G, Stengl, M, Thomas, D, Zaza, A, Remme, C, Heijman, J, Odening K. E., Gomez A. -M., Dobrev D., Fabritz L., Heinzel F. R., Mangoni M. E., Molina C. E., Sacconi L., Smith G., Stengl M., Thomas D., Zaza A., Remme C. A., and Heijman J.

Abstract

Cardiac arrhythmias are a major cause of death and disability. A large number of experimental cell and animal models have been developed to study arrhythmogenic diseases. These models have provided important insights into the underlying arrhythmia mechanisms and translational options for their therapeutic management. This position paper from the ESC Working Group on Cardiac Cellular Electrophysiology provides an overview of (i) currently available in vitro, ex vivo, and in vivo electrophysiological research methodologies, (ii) the most commonly used experimental (cellular and animal) models for cardiac arrhythmias including relevant species differences, (iii) the use of human cardiac tissue, induced pluripotent stem cell (hiPSC)-derived and in silico models to study cardiac arrhythmias, and (iv) the availability, relevance, limitations, and opportunities of these cellular and animal models to recapitulate specific acquired and inherited arrhythmogenic diseases, including atrial fibrillation, heart failure, cardiomyopathy, myocarditis, sinus node, and conduction disorders and channelopathies. By promoting a better understanding of these models and their limitations, this position paper aims to improve the quality of basic research in cardiac electrophysiology, with the ultimate goal to facilitate the clinical translation and application of basic electrophysiological research findings on arrhythmia mechanisms and therapies.

Published
2021

16. Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis

Author

Dicuonzo, S, Pedretti, S, Mangoni, M, Monari, F, Fanetti, G, Borsatti, E, Lombardi, D, Vianello, F, Iacobone, M, Corvo, R, Magrini, S, Pappagallo, G, Arcangeli, S, D'Angelillo, R, Dicuonzo S., Pedretti S., Mangoni M., Monari F., Fanetti G., Borsatti E., Lombardi D., Vianello F., Iacobone M., Corvo R., Magrini S. M., Pappagallo G., Arcangeli S., D'Angelillo R. M., Dicuonzo, S, Pedretti, S, Mangoni, M, Monari, F, Fanetti, G, Borsatti, E, Lombardi, D, Vianello, F, Iacobone, M, Corvo, R, Magrini, S, Pappagallo, G, Arcangeli, S, D'Angelillo, R, Dicuonzo S., Pedretti S., Mangoni M., Monari F., Fanetti G., Borsatti E., Lombardi D., Vianello F., Iacobone M., Corvo R., Magrini S. M., Pappagallo G., Arcangeli S., and D'Angelillo R. M.

Abstract

Background: Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated. Methods: The panel of the Italian Association of Radiotherapy and Clinical Oncology developed a clinical recommendation on the addition of EBRT to radioiodine after surgery for locally advanced differentiated thyroid cancer by using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the Evidence to Decision framework. A systematic review with meta-analysis about this topic was conducted with a focus on outcome of benefits and toxicity. Results: Locoregional control was improved by EBRT while no considerable toxicity impact was reported. Conclusion: The panel judged uncertain the benefit/harms balance; final recommendation was conditional both for EBRT + radioiodine and radioiodine alone in the adjuvant setting.

Published
2021

19. The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review

Author

Lancellotta, Valentina, Del Regno, L., Di Stefani, Alessandro, Fionda, Bruno, Marazzi, Fabio, Rossi, Ernesto, Balducci, Mario, Pampena, R., Morganti, Alessio Giuseppe, Mangoni, M., Lebbe, C., Garbe, C., Longo, C., Schinzari, Giovanni, Tagliaferri, Luca, Peris, Ketty, Lancellotta V., Di Stefani A., Fionda B., Marazzi F., Rossi E., Balducci M. (ORCID:0000-0003-0398-9726), Morganti A. G., Schinzari G. (ORCID:0000-0001-6105-7252), Tagliaferri L. (ORCID:0000-0003-2308-0982), Peris K. (ORCID:0000-0002-5237-0463), Lancellotta, Valentina, Del Regno, L., Di Stefani, Alessandro, Fionda, Bruno, Marazzi, Fabio, Rossi, Ernesto, Balducci, Mario, Pampena, R., Morganti, Alessio Giuseppe, Mangoni, M., Lebbe, C., Garbe, C., Longo, C., Schinzari, Giovanni, Tagliaferri, Luca, Peris, Ketty, Lancellotta V., Di Stefani A., Fionda B., Marazzi F., Rossi E., Balducci M. (ORCID:0000-0003-0398-9726), Morganti A. G., Schinzari G. (ORCID:0000-0001-6105-7252), Tagliaferri L. (ORCID:0000-0003-2308-0982), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Aim of this study was to systematically review the literature to assess efficacy and safety of stereotactic radiotherapy (SRT) in combination with immunotherapy for the treatment of melanoma brain metastases (MBM). The literature was searched using PubMed, Scopus, and Embase. Studies comparing SRT plus immunotherapy versus SRT or immunotherapy alone were deemed eligible for inclusion. Two studies showed improved overall survival after SRT plus immunotherapy in melanoma cancer patients with brain metastases. Three studies reported data on LC and DFS showing as SRT plus immunotherapy did not improve local control and DFS rates. G3-G4 toxicity was reported in only one study (20% in the SRT plus immunotherapy group versus 23% in the immunotherapy group). Despite SRT plus concurrent immunotherapy seems associated with possible survival advantage and low ≥ G3 late toxicity rates, the quality of evidence is very low. Therefore, in patients with brain metastases from melanoma, SRT plus immunotherapy should be evaluated on an individual basis after discussion by a multidisciplinary team.

Published
2022

22. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterore in mCPRC: ARTO trial NCT03449719

Author

Francolini, G., primary, Detti, B., additional, Di Cataldo, V., additional, Caini, S., additional, Alitto, A.R., additional, Parisi, S., additional, Demofonti, C., additional, Bruni, A., additional, Ingrosso, G., additional, Timon, G., additional, Tagliagambe, A., additional, Aquilano, M., additional, Ciccone, L.P., additional, Salvestrini, V., additional, Frosini, G., additional, Cerbai, C., additional, Allegra, A., additional, Burchini, L., additional, Desideri, I., additional, Mangoni, M., additional, Meattini, I., additional, and Livi, L., additional

Published
2022
Full Text
View/download PDF

23. OC-0932 Preoperative radiation therapy in early breast cancer: phase II ROCK trial (NCT03520894)

Author

Visani, L., primary, Meattini, I., additional, Francolini, G., additional, Di Cataldo, V., additional, Becherini, C., additional, Nori, J., additional, Bernini, M., additional, Orzalesi, L., additional, Sanchez, L., additional, Scoccimarro, E., additional, Lucidi, S., additional, Bellini, C., additional, Desideri, I., additional, Scotti, V., additional, Doro, R., additional, Masi, L., additional, Loi, M., additional, Bianchi, S., additional, Mangoni, M., additional, and Livi, L., additional

Published
2022
Full Text
View/download PDF

24. OC-0935 Radiotherapy in patients receiving anthracyclines: phase 3 SAFE trial (NCT2236806) interim analysis

Author

Meattini, I., primary, Becherini, C., additional, Visani, L., additional, Desideri, I., additional, Simontacchi, G., additional, Scotti, V., additional, Detti, B., additional, Francolini, G., additional, Loi, M., additional, Greto, D., additional, Bonomo, P., additional, Mangoni, M., additional, Barletta, G., additional, and Livi, L., additional

Published
2022
Full Text
View/download PDF

30. PO-1417 Impact of preoperative radiotherapy in surgically treated Ewing Sarcoma

Author

Ganovelli, M., primary, Frosini, G., additional, Loi, M., additional, Greto, D., additional, Guerrieri, B., additional, Mattioli, C., additional, Cerbai, C., additional, Lorenzetti, V., additional, Campanacci, D.A., additional, Caporalini, C., additional, Muratori, F., additional, Scoccianti, G., additional, Mangoni, M., additional, and Livi, L., additional

Published
2021
Full Text
View/download PDF

31. PO-1393 ARTO (NCT03449719), quality of life monocentric report after stereotactic treatment and abiraterone

Author

Francolini, G., primary, Di Cataldo, V., additional, Detti, B., additional, Lucidi, S., additional, Scoccimarro, E., additional, Mariotti, M., additional, Peruzzi, A., additional, Guerrieri, B., additional, Garlatti, P., additional, Loi, M., additional, Mangoni, M., additional, Desideri, I., additional, Meattini, I., additional, and Livi, L., additional

Published
2021
Full Text
View/download PDF

32. PO-1444 Determinants of radioresistance and progression-free interval in SBRT-treated spinal metastases

Author

Aquilano, M., primary, Lucidi, S., additional, Mauro, L., additional, Francolini, G., additional, Simontacchi, G., additional, Greto, D., additional, Desideri, I., additional, Bonomo, P., additional, Allegra, A.G., additional, Mariotti, M., additional, Masi, L., additional, Doro, R., additional, Bonucci, I., additional, Di Cataldo, V., additional, Mangoni, M., additional, and Livi, L., additional

Published
2021
Full Text
View/download PDF

33. PO-1138 Preoperative radiation therapy in breast cancer: preliminary results from ROCK trial (NCT03520894)

Author

Di Cataldo, V., primary, Francolini, G., additional, Visani, L., additional, Becherini, C., additional, Scoccimarro, E., additional, Masi, L., additional, Doro, R., additional, Salvatore, G., additional, Bianchi, S., additional, Vezzosi, V., additional, Lemmi, E., additional, Nori, J., additional, Sanchez, L., additional, Orzalesi, L., additional, Bernini, M., additional, Loi, M., additional, Desideri, I., additional, Mangoni, M., additional, Meattini, I., additional, and Livi, L., additional

Published
2021
Full Text
View/download PDF

35. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review

Author

Tagliaferri, Luca, Lancellotta, V., Fionda, B., Mangoni, M., Casa, Cristina, Di Stefani, Alessandro, Pagliara, Monica Maria, D'Aviero, A., Schinzari, Giovanni, Chiesa, Silvia, Mazzarella, Maria Cristina, Manfrida, Stefania, Colloca, Giuseppe Ferdinando, Marazzi, Fabio, Morganti, Alessio Giuseppe, Blasi, Maria Antonietta, Peris, Ketty, Tortora, Giampaolo, Valentini, Vincenzo, Tagliaferri L. (ORCID:0000-0003-2308-0982), Casa C., Di Stefani A., Pagliara M. M., Schinzari G. (ORCID:0000-0001-6105-7252), Chiesa S. (ORCID:0000-0003-0168-3459), Mazzarella C., Manfrida S., Colloca G. F., Marazzi F., Morganti A. G., Blasi M. A. (ORCID:0000-0001-7393-7644), Peris K. (ORCID:0000-0002-5237-0463), Tortora G. (ORCID:0000-0002-1378-4962), Valentini V. (ORCID:0000-0003-4637-6487), Tagliaferri, Luca, Lancellotta, V., Fionda, B., Mangoni, M., Casa, Cristina, Di Stefani, Alessandro, Pagliara, Monica Maria, D'Aviero, A., Schinzari, Giovanni, Chiesa, Silvia, Mazzarella, Maria Cristina, Manfrida, Stefania, Colloca, Giuseppe Ferdinando, Marazzi, Fabio, Morganti, Alessio Giuseppe, Blasi, Maria Antonietta, Peris, Ketty, Tortora, Giampaolo, Valentini, Vincenzo, Tagliaferri L. (ORCID:0000-0003-2308-0982), Casa C., Di Stefani A., Pagliara M. M., Schinzari G. (ORCID:0000-0001-6105-7252), Chiesa S. (ORCID:0000-0003-0168-3459), Mazzarella C., Manfrida S., Colloca G. F., Marazzi F., Morganti A. G., Blasi M. A. (ORCID:0000-0001-7393-7644), Peris K. (ORCID:0000-0002-5237-0463), Tortora G. (ORCID:0000-0002-1378-4962), and Valentini V. (ORCID:0000-0003-4637-6487)

Abstract

Melanoma is an extremely aggressive tumor and is considered to be an extremely immunogenic tumor because compared to other cancers it usually presents a well-expressed lymphoid infiltration. The aim of this paper is to perform a multidisciplinary comprehensive review of the evidence available about the combination of radiotherapy and immunotherapy for melanoma. Radiation, in fact, can increase tumor antigens visibility and promote priming of T cells but can also exert immunosuppressive action on tumor microenvironment. Combining radiotherapy with immunotherapy provides an opportunity to increase immunostimulatory potential of radiation. We therefore provide the latest clinical evidence about radiobiological rationale, radiotherapy techniques, timing, and role both in advanced and systemic disease (with a special focus on ocular melanoma and brain, liver, and bone metastases) with a particular attention also in geriatric patients. The combination of immunotherapy and radiotherapy seems to be a safe therapeutic option, supported by a clear biological rationale, even though the available data confirm that radiotherapy is employed more for metastatic than for non-metastatic disease. Such a combination shows promising results in terms of survival outcomes; however, further studies, hopefully prospective, are needed to confirm such evidence.

Published
2021

42. Naturally-occurring alkaloids of plant origin as potential antimicrobials against antibiotic-resistant infections

Author

Casciaro, B., Mangiardi, L., Cappiello, F., Romeo, I., Loffredo, M. R., Iazzetti, Antonia, Calcaterra, A., Goggiamani, A., Ghirga, F., Mangoni, M. L., Botta, B., Quaglio, D., Iazzetti A. (ORCID:0000-0002-7792-774X), Casciaro, B., Mangiardi, L., Cappiello, F., Romeo, I., Loffredo, M. R., Iazzetti, Antonia, Calcaterra, A., Goggiamani, A., Ghirga, F., Mangoni, M. L., Botta, B., Quaglio, D., and Iazzetti A. (ORCID:0000-0002-7792-774X)

Abstract

Antibiotic resistance is now considered a worldwide problem that puts public health at risk. The onset of bacterial strains resistant to conventional antibiotics and the scarcity of new drugs have prompted scientific research to re-evaluate natural products as molecules with high biological and chemical potential. A class of natural compounds of significant importance is represented by alkaloids derived from higher plants. In this review, we have collected data obtained from various research groups on the antimicrobial activities of these alkaloids against conventional antibiotic-resistant strains. In addition, the structure-function relationship was described and commented on, highlighting the high potential of alkaloids as antimicrobials.

Published
2020

43. Platform session

Author

Feigl, G., Rosmarin, W., Weninger, B., Likar, R., Hoogland, P. V., Groen, R. J. M., Vorster, W., Grobbelaar, M., Muller, C. J. F., du Toit, D. F., Moriggl, B., Greher, M., Klauser, A., Eichenberger, U., Prades, J. M., Timoshenko, A., Faye, M., Martin, C. H., Baroncini, M., Baiz, H., Ben Henda, A., Fontaine, C., Baksa, G., Toth, M., Patonay, L., Gonçalves-Ferreira, A., Gonçalves, C., Neto, L., Fonseca, T., Gaspar, H., Rino, J., Fernandes, M., Fernandes, P., Cardoso, H., Miranda, B., Rego, J., Hamel, A., Guillouche, P., Hamel, O., Garçon, M., Lager, S., Blin, Y., Armstrong, O., Robert, R., Rogez, J. M., Le Borgne, J., Kahilogulları, G., Comert, A., Esmer, A. F., Tuccar, E., Tekdemir, I., Ozdemir, M., Odabasi, A. B., Elhan, A., Anand, M. K., Singh, P. R., Verma, M., Raibagkar, C. J., Kim, H. J., Kwak, H. H., Hu, K. S., Francke, J. P., Macchi, V., Porzionato, A., Parenti, A., Metalli, P., Zanon, G. F., De Caro, R., Bernardes, A., Dionísio, J., Messias, P., Patrício, J., Apaydin, N., Uz, A., Evirgen, O., Shim, K. S., Park, H. D., Youn, K. H., Cajozzo, M., Bartolotta, T., Cappello, F., Sunseri, A., Romeo, M., Altieri, G., Modica, G., La Barbera, G., La Marca, G., Valentino, F., Valentino, B., Martino, A., Dees, G., Kleintjes, W. A., Williams, R., Herpe, B., Leborgne, J., Lagier, S., Cordova, A., Pirrello, R., Moschella, F., Mahajan, M. V., Bhat, U. B., Abhayankar, S. V., Ambiye, M. V., Kachlík, D. K., Stingl, J. S., Sosna, B. S., Fára, P. F., Lametschwandtner, A. L., Minnich, B. M., Straka, Z. S., Ifrim, M., Ifrim, C. Feng, Botea, M., Latorre, R., Sun, F., Henry, R., Crisóstomo, V., Cano, F. Gil, Usón, J., Mtez-Gomaríz, F., Climent, S., Hurmusiadis, V., Barrick, S., Barrow, J., Clifford, N., Morgan, F., Wilson, R., Wiseman, L., Fogg, O. A., Loukas, M., Tedman, R. A., Capaccioli, N., Capaccioli, L., Mannini, A., Guazzi, G., Mangoni, M., Paternostro, F., Vagnoli, P. Terrosi, Gulisano, M., Pacini, S., Grignon, B., Jankowski, R., Hennion, D., Zhu, X., Roland, J., Mutiu, G., Tessitore, V., Uzzo, M. L., Bonaventura, G., Milio, G., Spatola, G. F., Ilkan, T., Selcuk, T., Mustafa, A. M., Hamdi, C. H., Emel, T. C., Faruk, U., Hamdi, C. H., Bulent, G., Báča, V., Doubková, A., Kachlík, D., Stingl, J., Saylam, C., Kitiş, Ö., Üçerler, H., Manisahı, E., Gönül, A. S., Dashti, G. H. R., Nematbaksh, M., Mardani, M., Hami, J., Rezaian, M., Radmehr, B., Akbari, M., Paryani, M. R., Gilanpour, H., Zamfir, C., Zamfir, M., Lupusoru, C., Raileanu, C., Lupusoru, R., Bordei, P., Iliescu, D., Şapte, E., Adam, S., Baker, C., Sergi, C., Barberini, F., Ripani, M., Di Nitto, V., Zani, A., Magnosi, F., Heyn, R., Familiari, G., Elgin, U., Demiryurek, D., Berker, N., Ilhan, B., Simsek, T., Batman, A., Bayramoglu, A., Fogg, Q. A., Bartczak, A., Kamionek, M., Kiedrowski, M., Fudalej, M., Wagner, T., Artibani, W., Tiengo, C., Taglialavoro, G., Mazzoleni, F., Scapinelli, R., Ardizzone, E., Cannella, V., Peri, D., Pirrone, R., and Peri, G.

Published
2005
Full Text
View/download PDF

46. PD-0067: An ex vivo assay to detect radiosensitization by PARP-inhibitors in soft tissue sarcomas

Author

Mangoni, M., primary, Salvatore, G., additional, Greto, D., additional, Sottili, M., additional, Talamonti, C., additional, Lorenzetti, V., additional, Aquilano, M., additional, Peruzzi, A., additional, Salvestrini, V., additional, Visani, L., additional, Bonomo, P., additional, Scorianz, M., additional, Muratori, F., additional, Scoccianti, G., additional, Campanacci, D.A., additional, and Livi, L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results